Viatris Inc.
Viatris Inc. is a global healthcare company focused on generics and biosimilars, with its primary political signal being a direct equity holding by a former president ($1,001-$15,000) and a single congressional purchase.
BusinessWhat VTRS does
Viatris operates as a global pharmaceutical company formed from the merger of Mylan and Upjohn. Its business model centers on developing, manufacturing, and commercializing a broad portfolio of generic, branded, and complex generic medicines, including biosimilars. Revenue is derived from sales across multiple therapeutic areas and geographic markets.
12 months past · 3 months futureVTRS activity timeline
Executive Branch ConflictsVTRS held by Trump-administration officials
Lifetime Government AwardsVTRS federal contracts
VTRS doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding VTRS
Politicians Trading VTRSMembers of Congress with recent VTRS positions
Congressional TradesWho in Congress is trading VTRS
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting VTRSLive legislation impacting this stock
Political ProfileWhere VTRS sits in Washington
[object Object]
STRUCTURAL: No lobbying spend (`get_political_influence.lobbying.total_income`: $0), no donations, no federal contracts. EVIDENTIARY: Direct equity holding by Donald J. Trump (`get_executive_branch_exposure.by_ticker[0].holdings`) and one congressional purchase. Net: Signals are isolated and not supported by broader political engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
High exposure to healthcare pricing and drug approval legislationCongress, HHS, FDA"`Recent bill_impacts` shows 8 healthcare bills with material estimated revenue impacts, ranging from $3.19M to $6.06M."
Regulatory opportunities
-
Potential for favorable generic/biosimilar policy in pending billsCongress, FDA"`Recent bill_impacts` indicates multiple active healthcare bills, though specific carveouts for VTRS are absent (`Recent bill_carveouts` is empty)."
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for VTRS — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades VTRS
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord